Clin2
NCT06191731Worth exploringRecruiting

How the body gets rid of MRI contrast dye

Magnetic Resonance Imaging

This study looks at how gadolinium, a contrast agent used in MRI scans, leaves the body through urine. It aims to learn more about how the drug is processed.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
60 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older
  • You have a prescription for an MRI with contrast dye
  • You have health insurance
  • You can give written permission to be in the study
  • You have no known allergy to gadolinium contrast agents
  • Your kidneys are working well (not on dialysis and no severe kidney disease)

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07620093Recruiting
Reducing contrast dye in hospital wastewater

This trial collects urine after a CT scan with contrast dye to study how to reduce dye in hospital wastewater. You may help by using a special urine collection device.

Milan, MI
NCT04373564Recruiting· Phase 4
Tracking brain and movement changes after repeated MRI contrast

This study looks at whether getting the MRI contrast dye multiple times over 5 years affects body movement and thinking skills. It compares people who had the dye repeatedly with people who have little or no exposure, using brain MRI scans and regular mental and movement testing.

Scottsdale, Arizona
NCT01130545Recruiting
MRI testing of different scan methods in older adults

This study tests different MRI imaging techniques to improve how scans look and measure targets. You may be able to join with or without a contrast dye, and you’ll need to travel to the NIH for follow-up visits.

Bethesda, Maryland
NCT06596616Enrolling by invitation
Comparing two MRI contrast agents for liver imaging

This trial tests whether a newer contrast agent, gadopiclenol, works as well as the standard one for liver scans. It might be an option if you need an MRI to check for liver disease, tumors, or treatment response.

New York, New York
NCT05314400Recruiting
MRI with contrast for metastatic colon cancer liver lesions

This trial studies an MRI technique using a contrast dye (gadopetate/gadolinium) to better look at liver lesions that may be colon cancer spread. It may help doctors more accurately assess which liver tumors are present and guide next steps.

London, Ontario
NCT06731829Not yet recruiting· Phase 2
Contrast agent for adults having brain or spinal cord MRI scans

This study tests a new contrast agent (a dye injected before an MRI) to see how well it works for people having brain or spinal cord scans. It aims to improve image quality so doctors can see lesions more clearly, which may help with diagnosis and treatment planning.

Beijing, Beijing Municipality

Hear when a new Magnetic Resonance Imaging trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.